Schistosomiasis
54
3
4
37
Key Insights
Highlights
Success Rate
97% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
1.9%
1 terminated out of 54 trials
97.4%
+10.9% vs benchmark
9%
5 trials in Phase 3/4
22%
8 of 37 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 37 completed trials
Clinical Trials (54)
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of the rSm-p80 + GLA-SE (SchistoShield®) Candidate Vaccine in Healthy Adults in Burkina Faso and Madagascar
Praziquantel in Children Under Age 4
Prevalence and Molecular Identification of Human Schistosomiasis
Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective
Sm-TSP-2 Schistosomiasis Vaccine in Healthy Ugandan Adults
Health Education Model Led by Community Health Volunteers.
Introduction of Arpraziquantel Treatment for Schistosomiasis Control in Preschool-aged Children in Endemic Areas: A Small-scale Public Health Intervention Study
Safety, Tolerability, and Immunogenicity Study of Sm-p80 + GLA-SE (SchistoShield(R)) Vaccine in Healthy Adults
Delivering a Multi-disease Screening Tool to Migrant Populations
Assessment of Infection Activity in Travelers and Migrants Diagnosed With Chronic Schistosomiasis
Female Genital Schistosomiasis in Migrant Women: A Pilot Study
Evaluation of a Comprehensive School Health Programme in Zambia
Single-sex Female Controlled Human Schistosomiasis Mansoni Infection
L-PZQ ODT in Schistosoma Infected Children
Effectiveness and Cost-effectiveness of Integrated Model for Malaria and Helminth Control
Sm-p80 Schistosomiasis Challenge Study
Schistosomiasis in Senegal
Repeated Controlled Human Schistosoma Mansoni Infection
Retrospective Study of Clinical Practice and Management of Imported Schistosomiasis in France
Feasibility and Safety of Combining Anti-malarial With Deworming Drugs in African Children